Webinar #3: Human living myocardial slices and multicellular heart organoids for pre-clinical drug and toxicity testing

Date and time: November 24, 2026, 15:00-15:45
Speaker: Prof. Dr. Christian Bär
Format: Online (Microsoft Teams)
Participation: Free of charge

Register for the webinar series

Stay informed and receive invitations, updates, and access links for all upcoming sessions.

Please complete this required field.

First name

required field

Please complete this required field.

Last name

required field

Please complete this required field.

Company/Institution

required field

Please complete this required field

Country

required field

Please complete this required field

Email address

required field

I have read the Data Protection Information and accept it. I confirm that I will participate in the webinar personally. The use of bots, AI assistants, or other automated systems, as well as the recording, transcription, storage, or sharing of webinar content without the organizer’s prior written consent, is prohibited.

Bitte füllen Sie das Pflichtfeld aus.

Please confirm Data Protection Information

required field

Unsubscribe?

About the Webinar Series

Bringing a new drug from early discovery to clinical application is a complex journey – one that requires deep mechanistic understanding, predictive models, and robust safety assessment.

At Fraunhofer ITEM, we bridge this gap. Our expertise in preclinical pharmacology and toxicology enables us to translate biological mechanisms into actionable data for decision-making in drug development. From advanced in vitro systems to translational in vivo models, we support our partners in developing safer and more effective therapies.

With our new webinar series, “From Mechanism to Market – Translational Strategies in Preclinical Pharmacology and Toxicology,” we open the door to our scientific approaches, technologies, and services.

Each session will provide a focused deep dive into a specific area of expertise – demonstrating how we help to address key challenges in pharmaceutical research and development.

What to expect from this series

Insights into state-of-the-art preclinical models and methods
Translational strategies connecting mechanistic research and clinical relevance
Case-based examples from drug development and safety assessment
Direct access to our experts and their scientific perspectives

Whether you are working in early discovery, translational research, or regulatory science, this series is designed to support your next step forward.

By registering, you will:

Receive calendar invites and Microsoft Teams access links
Get early information about upcoming topics and speakers
Become part of a targeted expert audience for future content and events

Past Webinars

29.9.2026

Webinar with Dr. Franziska Dahlmann

The session"Development of an Inhalable Anti-infective – From Bench to Bedside" addressed key preclinical questions in inhaled anti-infective development and demonstrated how efficacy, exposure and safety data can support translational decision-making.

More information to follow up on the topic:

Preclinical Pharmacology and Toxicology

22.6.2026

Webinar with Dr. Mania Ackermann

The Kick-off session "Immune Cell Technologies in Preclinical Research" introduced innovative approaches in immune cell-based models while demonstrating their relevance for translational pharmacology and toxicology.

More information to follow up on the topic:

Immune Cells derived from iPSCs

About our expertise

Our work in preclinical pharmacology and toxicology is grounded in a strong scientific foundation and a clear translational focus.

We combine:

Human-relevant in vitro models, including iPSC-based systems
Mechanistic insights into disease pathways and drug effects
Integrated strategies for efficacy and safety evaluation
Regulatory-aligned approaches supporting decision-making and risk assessment

Through this integrated portfolio, we help our partners move from mechanism to market - efficiently and with confidence.